These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18625165)

  • 1. Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy.
    Sica DA; Black HR
    Curr Hypertens Rep; 2008 Aug; 10(4):330-5. PubMed ID: 18625165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-blockers in the treatment of hypertension: new data, new directions.
    Weber MA; Bakris GL; Giles TD; Messerli FH
    J Clin Hypertens (Greenwich); 2008 Mar; 10(3):234-8. PubMed ID: 18326967
    [No Abstract]   [Full Text] [Related]  

  • 3. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers.
    Polónia J; Barbosa L; Silva JA; Bertoquini S
    Blood Press Monit; 2010 Oct; 15(5):235-9. PubMed ID: 20577082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasodilating versus first-generation β-blockers for cardiovascular protection.
    Fares H; Lavie CJ; Ventura HO
    Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-blockers: a review of their pharmacological and physiological diversity in hypertension.
    Ripley TL; Saseen JJ
    Ann Pharmacother; 2014 Jun; 48(6):723-33. PubMed ID: 24687542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
    Zepeda RJ; Castillo R; Rodrigo R; Prieto JC; Aramburu I; Brugere S; Galdames K; Noriega V; Miranda HF
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Realities of newer beta-blockers for the management of hypertension.
    Manrique C; Giles TD; Ferdinand KC; Sowers JR
    J Clin Hypertens (Greenwich); 2009 Jul; 11(7):369-75. PubMed ID: 19583633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-blockers for hypertension: are they going out of style?
    Che Q; Schreiber MJ; Rafey MA
    Cleve Clin J Med; 2009 Sep; 76(9):533-42. PubMed ID: 19726558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review.
    Carella AM; Antonucci G; Conte M; Di Pumpo M; Giancola A; Antonucci E
    Curr Diabetes Rev; 2010 Jul; 6(4):215-21. PubMed ID: 20459394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The vasodilatory beta-blockers.
    Pedersen ME; Cockcroft JR
    Curr Hypertens Rep; 2007 Aug; 9(4):269-77. PubMed ID: 17686376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nephroprotective properties of third-generation beta-adrenoblockers].
    Kuz'min OB; Belianin VV; Zhezha VV
    Eksp Klin Farmakol; 2014; 77(3):40-3. PubMed ID: 24800526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol).
    DiNicolantonio JJ; Lavie CJ; Fares H; Menezes AR; O'Keefe JH
    Am J Cardiol; 2013 Mar; 111(5):765-9. PubMed ID: 23290925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of vasodilating beta-blockers in patients with complicated hypertension: focus on nebivolol.
    Giles TD
    Am J Med; 2010 Jul; 123(7 Suppl 1):S16-20. PubMed ID: 20609694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update.
    Black HR; Greenberg BH; Weber MA
    Am J Med; 2010 Nov; 123(11):S2. PubMed ID: 21035578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.
    Van Bortel LM; Fici F; Mascagni F
    Am J Cardiovasc Drugs; 2008; 8(1):35-44. PubMed ID: 18303936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-adrenoceptor antagonists in elderly patients with chronic heart failure: therapeutic potential of third-generation agents.
    Coats AJ
    Drugs Aging; 2006; 23(2):93-9. PubMed ID: 16536633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial.
    Studinger P; Tabák ÁG; Chen CH; Salvi P; Othmane TE; Torzsa P; Kapocsi J; Fekete BC; Tislér A
    J Clin Hypertens (Greenwich); 2013 Dec; 15(12):910-7. PubMed ID: 24119182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of carvedilol in hypertension: an update.
    Leonetti G; Egan CG
    Vasc Health Risk Manag; 2012; 8():307-22. PubMed ID: 22661898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function.
    Lombardo RM; Reina C; Abrignani MG; Rizzo PA; Braschi A; De Castro S
    Am J Cardiovasc Drugs; 2006; 6(4):259-63. PubMed ID: 16913827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade.
    Bakris G
    J Cardiovasc Pharmacol; 2009 May; 53(5):379-87. PubMed ID: 19454898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.